Literature DB >> 7790813

CD43 is a murine T cell costimulatory receptor that functions independently of CD28.

A I Sperling1, J M Green, R L Mosley, P L Smith, R J DiPaolo, J R Klein, J A Bluestone, C B Thompson.   

Abstract

Costimulation mediated by the CD28 receptor has been shown to play an important role in the development of a vigorous T cell immune response. Nevertheless, CD28-deficient mice can mount effective T cell-dependent immune responses. These data suggest that other costimulatory molecules may play a role in T cell activation. In a search for other costimulatory receptors on T cells, we have characterized a monoclonal antibody (mAb) that can costimulate T cells in the absence of accessory cells. Similar to CD28 antibodies, this mAb, R2/60, was found to synergize with T cell receptor engagement in inducing proliferation. Independent ligation of CD3 and the ligand recognized by R2/60 results in T cell proliferation, suggesting that the two molecules do not have to colocalize to activate the R2/60 costimulatory pathway. R2/60 does not react with CD28, and furthermore, R2/60 costimulates in a CD28-independent fashion since the mAb costimulates T cells from the CD28-deficient mice as well as wild-type mice. Expression cloning of the R2/60 antigen identified the ligand as murine CD43. Together, these data demonstrate that CD43 can serve as a receptor on T cells that can provide CD28-independent costimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790813      PMCID: PMC2192086          DOI: 10.1084/jem.182.1.139

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

Review 1.  Costimulation of T-cell growth.

Authors:  Y Liu; P S Linsley
Journal:  Curr Opin Immunol       Date:  1992-06       Impact factor: 7.486

2.  CD43 interferes with T-lymphocyte adhesion.

Authors:  B Ardman; M A Sikorski; D E Staunton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

4.  Targeted disruption of CD43 gene enhances T lymphocyte adhesion.

Authors:  N Manjunath; R S Johnson; D E Staunton; R Pasqualini; B Ardman
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

5.  Differential T cell costimulatory requirements in CD28-deficient mice.

Authors:  A Shahinian; K Pfeffer; K P Lee; T M Kündig; K Kishihara; A Wakeham; K Kawai; P S Ohashi; C B Thompson; T W Mak
Journal:  Science       Date:  1993-07-30       Impact factor: 47.728

6.  CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes.

Authors:  V Bazil; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes.

Authors:  N K Damle; K Klussman; P S Linsley; A Aruffo
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

Review 8.  CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development.

Authors:  I S Trowbridge; M L Thomas
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

9.  Differential epitope expression of Ly-48 (mouse leukosialin).

Authors:  C M Baecher-Allan; J D Kemp; K S Dorfman; R K Barth; J G Frelinger
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 10.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07
View more
  28 in total

1.  CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA.

Authors:  O C Farokhzad; J M Teodoridis; H Park; M A Arnaout; C S Shelley
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

Review 2.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

Review 3.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

5.  CD43-independent augmentation of mouse T-cell function by glycoprotein cleaving enzymes.

Authors:  Scott B Berger; Amir A Sadighi Akha; Richard A Miller; Gonzalo G Garcia
Journal:  Immunology       Date:  2006-06-23       Impact factor: 7.397

6.  Upregulation of ICOS on CD43+ CD4+ murine small intestinal intraepithelial lymphocytes during acute reovirus infection.

Authors:  Dina Montufar-Solis; Tomas Garza; Ba-Bie Teng; John R Klein
Journal:  Biochem Biophys Res Commun       Date:  2006-02-17       Impact factor: 3.575

7.  CD43-mediated IFN-γ production by CD8+ T cells promotes abdominal aortic aneurysm in mice.

Authors:  Hui-fang Zhou; Huimin Yan; Judy L Cannon; Luke E Springer; Jonathan M Green; Christine T N Pham
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

8.  CD43 Expression Regulated by IL-12 Signaling Is Associated with Survival of CD8 T Cells.

Authors:  Jee-Boong Lee; Jun Chang
Journal:  Immune Netw       Date:  2010-10-31       Impact factor: 6.303

9.  An alternative mode of CD43 signal transduction activates pro-survival pathways of T lymphocytes.

Authors:  Maria Elena Bravo-Adame; Rosario Vera-Estrella; Bronwyn J Barkla; Cecilia Martínez-Campos; Angel Flores-Alcantar; Jose Pablo Ocelotl-Oviedo; Gustavo Pedraza-Alva; Yvonne Rosenstein
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

10.  Activation and Costimulation of Intestinal T Cells: Independent and Collaborative Involvement of CD43, OX40, and Ly-6C.

Authors:  Dina Montufar-Solis; John R Klein
Journal:  Curr Immunol Rev       Date:  2005-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.